Clinical trial
Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV…
NCT00006262 · Northwestern University, Other · Terminated
Key facts
| NCT number | NCT00006262 |
|---|---|
| Title | Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer |
| Official title | A Phase 2 Study of BMY-27557-14 (a Rebeccamycin Analog) in Patients With Ovarian Cancer |
| Lead sponsor | Northwestern University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | becatecarin |
| Start date | Jul 1, 2000 |
| Primary completion | Sep 1, 2001 |
| Completion | Sep 1, 2001 |
| First posted | Mar 25, 2004 |
| Last update posted | Jun 11, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: